Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials

David S. SiegelDivision of Multiple Myeloma, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA; Correspondence[email protected]

Katja C. WeiselDepartment of Hematology, Oncology, Immunology, Rheumatology and Pulmonology, University Hospital of Tübingen, Tübingen, Germany;

Meletios A. DimopoulosDepartment of Clinical Therapeutics at the University, National and Kapodistrian University of Athens School of Medicine, Athens, Greece;

Rachid BazDepartment of Malignant Hematology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA;

Paul RichardsonMyeloma Program, Dana-Farber Cancer Institute, Boston, MA, USA;

Michel DelforgeDepartment of Hematology, University Hospitals Leuven, Leuven, Belgium;

Kevin W. SongDivision of Hematology, Vancouver General Hospital, Vancouver, British Columbia, Canada;

Jesus F. San MiguelDirector of Clinical and Translational Medicine, Clinica Universidad de Navarra, CIMA, IDISNA, Pamplona, Spain;

Philippe MoreauHematology Department, CHU Hotel Dieu-CHU de Nantes, France;

Hartmut GoldschmidtDepartment of Medicine V, University of Heidelberg, Heidelberg, Germany;

Michele Cavo“Seràgnoli” Institute of Hematology, Bologna University School of Medicine, Bologna, Italy;

Sundar JagannathTisch Cancer Institute, Mount Sinai Hospital, New York City, NY, USA;

Xin YuCelgene Corporation, Summit, NJ, USA;

Kevin HongCelgene Corporation, Summit, NJ, USA;

Lars SternasCelgene Corporation, Summit, NJ, USA;

Mohamed ZakiCelgene Corporation, Summit, NJ, USA;

Antonio PalumboDepartment of Hematology, University of Turin, Turin, Italy

show all

Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date